<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38653">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02100722</url>
  </required_header>
  <id_info>
    <org_study_id>FAME 3</org_study_id>
    <nct_id>NCT02100722</nct_id>
  </id_info>
  <brief_title>A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease</brief_title>
  <acronym>FAME 3</acronym>
  <official_title>Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) 3 Trial A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cardiovascular Center Aalst, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catharina Hospital Eindhoven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Golden Jubilee National Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genae</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Fractional flow reserve (FFR, (coronary
      pressure wire-based index for assessing the ischemic potential of a coronary lesion)-guided
      percutaneous coronary intervention (PCI) in patients with multivessel coronary artery
      disease (CAD) will result in similar outcomes to coronary artery bypass graft surgery
      (CABG).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The FAME 3 trial is a multicenter, international, randomized, controlled noninferiority
      trial.  All patients with multivessel CAD (not involving the left main) will be screened by
      the site's Heart Team (including but not limited to an interventional cardiologist, cardiac
      surgeon and research coordinator).  If all agree that the patient can be treated either with
      FFR-guided PCI or CABG, and all inclusion criteria are met and no exclusion criteria are
      met, then the patient will be randomized.

      Baseline clinical, functional, laboratory and electrocardiographic data will be obtained.
      Patients will receive treatment within 4 weeks of randomization. Patients randomized to CABG
      will receive state of the art therapy at the discretion of the local surgeon with a strong
      emphasis on arterial revascularization.  Patients undergoing PCI will have FFR measured with
      a St. Jude Medical coronary pressure wire across all lesions.  If the FFR is ≤0.80, then PCI
      will be performed with the Medtronic Resolute Integrity drug-eluting stent (DES) as per
      usual routine.  If the FFR is &gt;0.80 then PCI will be deferred.

      All patients will receive medical therapy as per published guidelines. Patients will
      follow-up at 1 and 6 months, and 1 and 3 years with an evaluation of clinical status,
      functional status, medications and events. Follow-up may be extended to 5 years, if funding
      allows.

      Core lab analyses will include formal quantitative coronary angiography (QCA) of the
      baseline angiograms with calculation of the Synergy between Percutaneous Coronary
      Intervention with Taxus and Cardiac Surgery (SYNTAX) score and Functional SYNTAX Score.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>MACCE</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Death, MI, stroke and any repeat revascularization (MACCE) will be evaluated at 1 year, where subjects contribute data from time of randomization until the occurrence of MACCE or one year follow-up, whichever occurs first.  Subjects who die or are lost to follow up before 1 year will be censored at their last recorded activity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death, MI, and stroke</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Death, MI, and stroke will be evaluated at 3 years, where subjects contribute data from time of enrollment until the occurrence of one of the above events or three year follow-up, whichever occurs first.  Subjects who die or are lost to follow up before this time will be censored at their last recorded activity.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>MACCE</measure>
    <time_frame>2 years, 3 years, 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Death, MI, stroke and any repeat revascularization (MACCE) rate at 2 years, 3 years and 5 years</description>
  </other_outcome>
  <other_outcome>
    <measure>Death</measure>
    <time_frame>1 year, 2years, 3 years, 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Death will be evaluated at 1 year, 2 years, 3 years and 5 years,  excluding patients lost to follow-up from each arm</description>
  </other_outcome>
  <other_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>1 year, 2 years, 3 years and 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>MI will be evaluated at 1 year, 2 years, 3 years and 5 years,  excluding patients lost to follow-up from each arm</description>
  </other_outcome>
  <other_outcome>
    <measure>Stroke</measure>
    <time_frame>1 year, 2 years, 3 years and 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Stroke will be evaluated at  1 year, 2 years, 3 years and 5 years,  excluding patients lost to follow-up from each arm</description>
  </other_outcome>
  <other_outcome>
    <measure>Repeat revascularization</measure>
    <time_frame>1 year, 2 years, 3 years and 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Any repeat revascularization will be evaluated at 1 year, 2 years, 3 years and 5 years,  excluding patients lost to follow-up from each arm</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Coronary Disease</condition>
  <condition>Coronary Stenosis</condition>
  <arm_group>
    <arm_group_label>FFR guided PCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergoing PCI will have FFR measured with a St. Jude Medical coronary pressure wire across all lesions.  If the FFR is ≤0.80, then PCI will be performed with the Medtronic Resolute Integrity drug-eluting stent (DES) as per usual routine.  If the FFR is &gt;0.80 then PCI will be deferred. Only those sites with prior experience measuring FFR will be included in the FAME 3 trial.  These patients in whom FFR of a particular lesion was not possible will be included in all analyses based on the intention to treat principle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CABG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CABG will be performed as per clinical routine at each participating center. Both off-pump and on-pump surgery are acceptable, as long as the surgeon and the site are experienced in the particular technique.  An internal mammary graft to the LAD should be attempted in all cases, if feasible.  Complete arterial revascularization is strongly recommended, however, each center should use a conduit strategy with which they are most comfortable.  All vessels ≥ 1,5 mm in diameter and with ≥ 50% stenosis should be bypassed, if technically feasible.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>FFR guided PCI</intervention_name>
    <arm_group_label>FFR guided PCI</arm_group_label>
    <other_name>Fractional Flow Reserve-Guided PCI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CABG</intervention_name>
    <arm_group_label>CABG</arm_group_label>
    <other_name>Coronary Artery Bypass Graft Surgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Age ≥ 21 years with angina and/or evidence of myocardial ischemia

          -  2. Three vessel CAD, defined as ≥ 50% diameter stenosis by visual   estimation in
             each of the three major epicardial vessels or major side branches, but not involving
             left main coronary artery, and amenable to revascularization by both PCI and CABG as
             determined by the Heart Team. Patients with a non-dominant right coronary artery may
             be included if only the left anterior descending artery (LAD) and left circumflex
             have ≥50% stenosis

          -  3. Willing and able to provide informed, written consent

        Exclusion Criteria:

          -  1. Requirement for other cardiac or non-cardiac surgical procedure (e.g.,  valve
             replacement, carotid revascularization)

          -  2. Cardiogenic shock and/or need for mechanical/pharmacologic hemodynamic support

          -  3. Recent STEMI (&lt;5 days prior to randomization)

          -  4. Ongoing Non STEMI with biomarkers (cardiac troponin) still rising

          -  5. Known left ventricular ejection fraction &lt;30%

          -  6. Life expectancy &lt; 2 years

          -  7. Requiring renal replacement therapy

          -  8. Undergoing evaluation for organ transplantation

          -  9. Participation or planned participation in another clinical trial, except for
             observational registries

          -  10. Pregnancy

          -  11. Inability to take dual antiplatelet therapy for six months

          -  12. Previous CABG

          -  13. Left main disease requiring revascularization

          -  14. Extremely calcified or tortuous vessels precluding FFR measurement

          -  15. Any target lesion with in-stent drug-eluting stent restenosis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William F Fearon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nico HJ Pijls, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catharina Hospital Eindhoven, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernard De Bruyne, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Center Aalst, Belgium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>William F Fearon, MD</last_name>
    <phone>650-725-2621</phone>
    <email>wfearon@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frederik M Zimmermann, MD</last_name>
    <phone>0031402398360</phone>
    <email>frederik.zimmermann@cze.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-2004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>William F Fearon, MD</last_name>
      <phone>650-725-2621</phone>
      <email>wfearon@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>William F Fearon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta VA Medical Center</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jesse Brown VA Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>dgriza@uic.edu</email>
    </contact>
    <investigator>
      <last_name>Mladen Vidovich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northeast Cardiology Associates</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>cwhited@northeastcardiology.com</email>
    </contact>
    <investigator>
      <last_name>Peter Ver Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn Presbyterian Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>susanne.donovan@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>William H Matthai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VA North Texas Health Care System</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>michael.jessen@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Emmanouil Brilakis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>guspichard@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Augusto Pichard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Center Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>9300 Aalst</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernard de Bruyne, MD, PhD</last_name>
      <phone>003253 72 44 47</phone>
      <email>bernard.de.Bruyne@OLVZ-aalst.be</email>
    </contact>
    <investigator>
      <last_name>Bernard de Bruyne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Le'Centre Hospitalier de l'Universite de Montreal</name>
      <address>
        <city>Montreal</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>caroline.vallieres.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Samer Mansour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>philippe.l_lallier@icloud.com</email>
    </contact>
    <investigator>
      <last_name>Philippe L'Allier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Masaryk University and University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>jana.rutarova@cktch.cz</email>
    </contact>
    <investigator>
      <last_name>Petr Kala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Na Homolce Hospital</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>Liz.coling@homolka.cz</email>
    </contact>
    <investigator>
      <last_name>Martin Mates, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Engstroem, MD</last_name>
      <email>Thomas.engstroem@rh.regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Thomas Engstroem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Hospital</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>janine.salandre@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles Rioufol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hungarian Institute of Cardiology</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>Toth.gabr@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Zsolt Piroth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>sjpark@summitmd.com</email>
    </contact>
    <investigator>
      <last_name>Seung-Jung Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital Santariskiu Klinikos</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>jurgina.vaitkiene@santa.lt</email>
    </contact>
    <investigator>
      <last_name>Giedrius Davidavicius, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catharina Hospital Eindhoven</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nico HJ Pijls, MD, PhD</last_name>
      <phone>040-2398360</phone>
      <email>Nico.Pijls@inter.nl.net</email>
    </contact>
    <contact_backup>
      <last_name>Frederik M Zimmermann, MD</last_name>
      <phone>040-2398360</phone>
      <email>frederik.zimmermann@cze.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Nico HJ Pijls, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frederik M Zimmermann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>iatros007@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Branko Beleslin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Center Kragujevac</name>
      <address>
        <city>Kragujevac</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Institutet, Dep of clinical science and education, Södersjukhuset</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>malin.an.persson@sodersjukhuset.se</email>
    </contact>
    <investigator>
      <last_name>Nils Witt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Danderyds Sjukhus</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>hedvig.tjerneld@ds.se</email>
    </contact>
    <investigator>
      <last_name>Nikolaos Östlund Papadogeorgos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>gmanoharan@msn.com</email>
    </contact>
    <investigator>
      <last_name>Ganesh Manoharan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Golden Jubilee National Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>Joanne.kelly@gjnh.scot.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Keith G Oldroyd, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>joanne.jessup@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Philip MacCarthy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wythenshawe Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>Jaydeep.Sarma@UHSM.NHS.UK</email>
    </contact>
    <investigator>
      <last_name>Jaydeep Sarma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Serbia</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 7, 2014</lastchanged_date>
  <firstreceived_date>March 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
